The Federal Commission for the Protection against Health Risks (Cofepris) has issued a crucial warning to doctors and the general public about the Dangers associated with indiscriminate use of semaglutide and liraglutidetwo drugs that have gained popularity for their effectiveness in the treatment of type 2 diabetes mellitus and obesity.
However, the growing trend of using them without proper medical supervision has set off alarms in the health authority.
For several months now, semaglutide has been a topic of conversation on television programs and social networks, especially in the United States, where celebrities have promoted this product. injectable medication as a quick solution for weight loss.
Liraglutide has also been recognized for its ability to significantly reduce body weight within a few months. Although both drugs require a prescription, their sale has been reported through well-known online trading platforms and other electronic means, which facilitates their access without professional supervision.
Adverse effects and health risks
Cofepris has highlighted that the consumption of these medications without adequate medical supervision can cause a series of adverse effects. Among the most common are nausea, vomiting and diarrhea, which can lead to kidney damage.
Other effects include constipation, dizziness, mild tachycardia, infections, headache, dyspepsia, and skin reactions at the injection site. In addition, serious psychological problems have been reported: some countries have reported patients who developed suicidal thoughts and self-harming behavior after the use of GLP-1 agonists.
International Review and Recommendations
The European Medicines Agency (EMA) has reviewed these reports, concluding that there is not enough information to support a causal relationship between these medications and suicidal thoughts or actions.
However, the US Food and Drug Administration (FDA) has recommended close monitoring for depression and suicidal thoughts in patients using Wegovy (semaglutide) and Saxenda (liraglutide).
The Drug Information Center of the University of Córdoba has also addressed this issue, highlighting the need for caution due to the potential for suicidal ideation or behavior associated with liraglutide, in addition to its beneficial effects on glycemic control and weight loss.
Warning from Cofepris and Councils for the Population
Given these risks, Cofepris insists that GLP-1 agonist medications should be prescribed only by a specialist doctor. This professional will evaluate the patient, provide an appropriate diagnosis and monitor treatment on an ongoing basis.
The health authority has detected a worrying trend on social networks and entertainment platforms where The use of these products is promoted for rapid weight losswhich can lead to serious health consequences, including the possibility of death.
Cofepris also warns about the danger of self-medication and the consumption of these medications without an accurate diagnosis, which can cause excessive stress on vital organs such as the liver and pancreas, with the risk of their failure.
The recommendation is clear: do not purchase medications or any health supplies through online sales platforms, social networks or informal businesses. In addition, it is essential that the drugs present labeling in Spanish, health registration, batch and expiration date.
#Cofepris #warns #selfmedication #lose #weight #semaglutide #liraglutide